HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Lowers Price Target to $35
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $40 to $35.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and lowers the price target from $40 to $35.